Dr. Sara M. Tolaney on Neoadjuvant Treatment Considerations for TNBC

July 28, 2015
Sara M. Tolaney, MD, MPH

Sara M. Tolaney, MD, MPH, medical oncologist, Dana-Farber Cancer Institute, discusses neoadjuvant treatment considerations for patients with triple-negative breast cancer (TNBC).

Sara M. Tolaney, MD, MPH, medical oncologist, Dana-Farber Cancer Institute, discusses neoadjuvant treatment considerations for patients with triple-negative breast cancer (TNBC).

Related Content:

VideosBreast Cancer
Shorter Adjuvant Trastuzumab Has Long-Term Benefits for HER2+ Breast Cancer
Tailored Survivorship Care Is Needed in the Breast Cancer Space
Genetic Testing May Increase Fear of Recurrence